Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.

In the phase 2 study of tirasemtiv, no efficacy signal was seen in ALSFRS-R, although a key secondary end point, SVC, showed a nominally significant benefit. 9 , 11 , 12 SVC was the primary end point of the phase 3 tirasemtiv study; negative results were believed to reflect poor tolerability, as a per protocol post hoc analysis again suggested a benefit. 11 In the FORTITUDE-ALS trial, the phase 2 study of reldesemtiv, SVC was the primary outcom

also in 7,732 other papers